A pharmaceutical manufacturer was working with Fisher Clinical Services in support of multiple clinical trials and protocols. Patients enrolled in these trials were occasionally unable to maintain an appointment at their respective investigator site. The circumstances were many and varied. Examples included:
The Sponsor recognized that providing Direct-to-Patient service on an exception basis would meet a critical need. Because the patients participating in these trials were able to self-medicate, it was strictly the residential delivery that needed to be addressed.